Xarelto Indication Expansion Efforts Show That Fewer Could Be More
This article was originally published in The Pink Sheet Daily
J&J and Bayer continue quest for acute coronary syndrome claim following three rejections by FDA; this time, Xarelto will be tested on top of only one antiplatelet drug instead of two.
You may also be interested in...
J&J will be talking to FDA regarding expanded approval for peripheral arterial disease and coronary artery disease following early stop of COMPASS outcomes study; strong data will be needed if asymptomatic patients are targeted.
Daiichi Sankyo plans to file two once-daily doses of the edoxaban for stroke prevention in atrial fibrillation, but the lowest one was associated with more ischemic strokes compared to warfarin in the ENGAGE AF-TIMI 48 study, which could limit prospects for use.
The agency announces that it is evaluating unpublished findings based on pancreatic tissue specimens from a few deceased patients; clinicians say ongoing prospective studies will determine how diabetes drugs affect the pancreas.